Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arvinas Inc
(NQ:
ARVN
)
26.25
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arvinas Inc
< Previous
1
2
3
4
5
6
Next >
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer
July 31, 2023
Designation indicates entry into the U.K.’s Innovative Licensing and Access Pathway (ILAP)
From
Arvinas Inc.
Via
GlobeNewswire
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
July 06, 2023
Collaboration expands Carrick’s clinical-stage Oncology program
From
CARRICK THERAPEUTICS LIMITED
Via
GlobeNewswire
What 8 Analyst Ratings Have To Say About Arvinas
June 26, 2023
Via
Benzinga
6 Analysts Have This to Say About Arvinas
June 09, 2023
Via
Benzinga
Arvinas Announces Changes to its Board of Directors
June 15, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations
June 08, 2023
Arvinas Inc (NASDAQ: ARVN) announced interim data from its Phase 1/2 dose escalation and expansion trial of ARV-766 in metastatic
Via
Benzinga
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
June 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Looking Into Arvinas's Return On Capital Employed
May 19, 2023
Via
Benzinga
Where Arvinas Stands With Analysts
May 08, 2023
Via
Benzinga
Arvinas: Q1 Earnings Insights
May 05, 2023
Via
Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Warner Bros. Discovery To Rally Around 62%? Here Are 10 Other Analyst Forecasts For Monday
May 08, 2023
Wells Fargo raised the price target for Stanley Black & Decker, Inc. (NYSE: SWK) from $85 to $90. Wells Fargo analyst Joe O'Dea maintained an Equal-Weight rating. Stanley Black & Decker shares rose 3%...
Via
Benzinga
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 08, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Earnings Perspective: Return On Capital Employed
February 28, 2023
Via
Benzinga
6 Analysts Have This to Say About Arvinas
February 24, 2023
Via
Benzinga
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 05, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Stifel Targeted Oncology Day
April 21, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Where Arvinas Stands With Analysts
January 31, 2023
Via
Benzinga
Where Arvinas Stands With Analysts
January 12, 2023
Via
Benzinga
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership
April 03, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
February 27, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 23, 2023
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
February 06, 2023
From
Arvinas Inc.
Via
GlobeNewswire
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
January 13, 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.
Via
MarketBeat
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
January 09, 2023
Companies That Fell Through 52-Week Lows Monday During Monday's morning trading, 14 companies set new 52-week lows.
Via
Benzinga
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Arvinas Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.